Evaluating Using Rescue Therapies for CAR T cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome

This research study is being conducted to evaluate experimental rescue therapies for the treatment of cytokine release syndrome (CRS) and CAR T cell related HLH-like syndrome (CRHLS). These are both life-threatening side effects which can occur in some patients after infusion with a CAR T cell product. This consent allows for the use of an experimental drug called Tadekinig alfa, which may help improve CRS and CRHLS side effects. Experimental drugs are not approved by the FDA and are considered investigational. You may also be consented/enrolled to receive Tadekinig alfa prior to your CAR T cell infusion in anticipation of any serious side effects.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  CART,cytokine
• Age: Between 18 Years - 99 Years
• Gender: All